SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SIBIA Neurosciences (SIBI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LLCF who wrote (352)5/26/1999 11:58:00 AM
From: scaram(o)uche  Read Replies (1) of 579
 
>> Can't believe no one cares here. <<

Two thoughts...... first, it looks like this is providing an op for someone that needed to bail. Second, this deal could be good or bad, from what we've seen thus far. We'll need to see some guidance from the relatively few analysts that follow the company (and pray that the guidance is close). If the royalty ass'd with the option is %10 or less, it's a lousy deal IMO. If the royalty is >20%, it's a great deal. I'm guessing that the royalty ass'd with 3182 and other newer molecules will be in the neighborhood of 10%, given that Lilly adopts all development costs.

One other factor..... the biotech rally in top-tier and partial recovery in secondaries has led to the return of the "short" crew. Rallies are being cut short in several issues. While I don't expect that any of the shares being sold in SIBI are shorts, the fear-mongers *have* returned to pick at sector bones.

Not going to be boring!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News